Literature DB >> 11897601

Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.

Martin Bråbäck1, Kristian Riesbeck, Arne Forsgren.   

Abstract

The susceptibility pattern of Mycobacterium marinum was determined. Quinupristin-dalfopristin and telithromycin were less active than clarithromycin. Linezolid showed good antimicrobial activity at clinically achievable concentrations. Gatifloxacin, levofloxacin, and moxifloxacin displayed activities similar to those of ciprofloxacin. Gemifloxacin was less active. The Etest method showed variable agreement with the reference method.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11897601      PMCID： PMC127113          DOI： 10.1128/AAC.46.4.1114-1116.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.

Authors:  N Rastogi; K S Goh; M Berchel; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Mycobacterium balnei, a new acid-fast bacillus occurring in swimming pools and capable of producing skin lesions in humans.

Authors:  F LINELL; A NORDEN
Journal:  Acta Tuberc Scand Suppl       Date:  1954

3.  In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.

Authors:  J Fung-Tomc; B Minassian; B Kolek; T Washo; E Huczko; D Bonner
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

Review 4.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  H Tomioka; K Sato; T Akaki; H Kajitani; S Kawahara; M Sakatani
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Antimicrobial susceptibility of Mycobacterium marinum determined by E-test and agar dilution.

Authors:  J Werngren; B Olsson-Liljequist; L Gezelius; S E Hoffner
Journal:  Scand J Infect Dis       Date:  2001

7.  In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.

Authors:  M J Ruiz-Serrano; L Alcalá; L Martínez; M Díaz; M Marín; M J González-Abad; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Activities of linezolid against rapidly growing mycobacteria.

Authors:  R J Wallace; B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

9.  Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors:  D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

10.  Antibiotic susceptibility pattern of Mycobacterium marinum.

Authors:  A Aubry; V Jarlier; S Escolano; C Truffot-Pernot; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191
View more
  8 in total

Review 1.  Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.

Authors:  Elizabeth Ann Misch; Christopher Saddler; James Muse Davis
Journal:  Curr Infect Dis Rep       Date:  2018-03-19       Impact factor: 3.725

2.  Antibiotic Susceptibility of Mycobacteria Isolated from Ornamental Fish.

Authors:  Leszek Guz; Krzysztof Puk
Journal:  J Vet Res       Date:  2022-03-25       Impact factor: 2.058

3.  Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.

Authors:  Kelly M Pennington; Ann Vu; Douglas Challener; Christina G Rivera; F N U Shweta; John D Zeuli; Zelalem Temesgen
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-05-08

4.  Evaluation of the SLOMYCO Sensititre(®) panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates.

Authors:  Marion Chazel; Hélène Marchandin; Nicolas Keck; Dominique Terru; Christian Carrière; Michael Ponsoda; Véronique Jacomo; Gilles Panteix; Nicolas Bouzinbi; Anne-Laure Bañuls; Marc Choisy; Jérôme Solassol; Alexandra Aubry; Sylvain Godreuil
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-06       Impact factor: 3.944

5.  RepTB: a gene ontology based drug repurposing approach for tuberculosis.

Authors:  Anurag Passi; Neeraj Kumar Rajput; David J Wild; Anshu Bhardwaj
Journal:  J Cheminform       Date:  2018-05-21       Impact factor: 5.514

Review 6.  Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons.

Authors:  Claudio Piersimoni; Claudio Scarparo
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

7.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

8.  Invasive Mycobacterium marinum infections.

Authors:  Timothy Lahey
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.